Wordt geladen...
Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
INTRODUCTION: Pyroglutamate‐modified amyloid β (Aβ(pE3)) could be a biomarker for Aβ plaque pathology in the brain. An ultra‐high‐sensitive assay is needed for detecting Aβ(pE3‐40). METHODS: Immunomagnetic reduction was used for quantification of Aβ(pE3‐40) in plasma from 46 participants. The concen...
Bewaard in:
| Gepubliceerd in: | Alzheimers Dement (Amst) |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7191392/ https://ncbi.nlm.nih.gov/pubmed/32363230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dad2.12029 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|